Publications by authors named "A Skaro"
Article Synopsis
- Tranexamic acid is known to reduce bleeding and blood transfusions in various surgeries, but its effectiveness for patients undergoing liver resection due to cancer is uncertain.
- A multicenter randomized clinical trial involving 1384 patients was conducted to see if tranexamic acid decreases the need for red blood cell transfusions within 7 days after liver surgery.
- The results showed no significant difference in transfusion rates or blood loss between the tranexamic acid group and the placebo group, and those who received tranexamic acid experienced more complications.
Background: Previous studies report promising outcomes with minimally invasive (MIS) hepatectomy in elderly patients but remain limited by small size. This study aims to comparatively evaluate the demographics and outcomes of geriatric patients undergoing MIS and open hepatectomy.
Method: The 2016-2021 NSQIP database was evaluated comparing patients ≥75 undergoing MIS versus open hepatectomy.
Article Synopsis
- Normothermic regional perfusion (NRP) aims to enhance organ transplantation by reversing ischemic damage from planned donation after circulatory death, but faces ethical concerns delaying its use in Canada.
- Participants in a study—comprising donor families, organ recipients, and healthcare leaders—were interviewed to explore their perceptions of NRP's ethical implications, especially regarding the dead donor rule and brain reperfusion.
- The findings suggest that while stakeholders view NRP as ethically sound, their acceptance hinges on the belief that appropriate death criteria have been followed, indicating the need for empirical validation to maintain public trust in transplantation practices.
Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer.
Ann Hepatobiliary Pancreat Surg
May 2024
Backgrounds/aims: While patients with borderline resectable pancreatic cancer (BRPC) are a target population for neoadjuvant chemotherapy (NAC), formal guidelines for neoadjuvant therapy are lacking. We assessed the perioperative and oncological outcomes in patients with BRPC undergoing NAC with FOLFIRINOX for patients undergoing upfront surgery (US).
Methods: The AHPBA criteria for borderline resectability and/or a CA19-9 level > 100 μ/mL defined borderline resectable tumors retrieved from a prospectively populated institutional registry from 2007 to 2020.
Long-term patient and graft survival has been achieved in organ transplantation but at the expense of toxic side effects that are associated with long-term use of nonspecific immunosuppressive drugs. Discovering new regulators of dendritic cells is the key for development of an ideal treatment to prevent immune rejection. We hypothesized that knockdown of circMAP2K2 induces immunosuppressive DCs and that treatment with circMAP2K2 silenced-DCs can prevent alloimmune rejection.
View Article and Find Full Text PDF